Sun Pharma rebounds after crashing over 15% on dismal FY16 outlook

22 July 2015

Sun Pharmaceutical on Wednesday rebounded from over 15% plunge after the company said Tuesday it sees flat sales in fiscal 2016. India’s largest drugmaker by market value said the cost of integrating Ranbaxy will impact revenue and profits in 2016.

Shares in the company were trading up 3.2% on Wednesday.

The company in a statement said prolonged impact of remediation measures at Halol, and divestment of low margin assets will also hurt the bottom line in 2016. Halol contributes 10% of the company’s sales. Sun Pharma now sees flat-to-declining sales in fiscal year 2016 over FY15 on the back of delay in resolving the Halol challenge as well as the discontinuation of 2-3 low-margin businesses.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK